DE3001454C2 - - Google Patents
Info
- Publication number
- DE3001454C2 DE3001454C2 DE3001454A DE3001454A DE3001454C2 DE 3001454 C2 DE3001454 C2 DE 3001454C2 DE 3001454 A DE3001454 A DE 3001454A DE 3001454 A DE3001454 A DE 3001454A DE 3001454 C2 DE3001454 C2 DE 3001454C2
- Authority
- DE
- Germany
- Prior art keywords
- prostaglandin
- medicament according
- water
- dry particles
- carbohydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 claims description 47
- 229940079593 drug Drugs 0.000 claims description 28
- 150000003180 prostaglandins Chemical class 0.000 claims description 27
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 17
- 239000002245 particle Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 229960002986 dinoprostone Drugs 0.000 claims description 14
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 14
- 150000001720 carbohydrates Chemical class 0.000 claims description 11
- 235000014633 carbohydrates Nutrition 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 claims description 3
- 230000008961 swelling Effects 0.000 claims description 3
- 239000007966 viscous suspension Substances 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 230000001588 bifunctional effect Effects 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- 230000006855 networking Effects 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims 1
- -1 epichlorohydrin Chemical class 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000007924 injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 7
- 239000003708 ampul Substances 0.000 description 6
- 206010000210 abortion Diseases 0.000 description 5
- 231100000176 abortion Toxicity 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 210000003679 cervix uteri Anatomy 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 229940126601 medicinal product Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- STJFYCWYHROASW-UHFFFAOYSA-N O-methyl-glaucamine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C2OC(OC)C3=C4OCOC4=CC=C3C12 STJFYCWYHROASW-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010012186 Delayed delivery Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000012052 hydrophilic carrier Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7900737A SE431821B (sv) | 1979-01-29 | 1979-01-29 | Lagringsstabilt, prostaglandininnehallande medicinskt preparat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3001454A1 DE3001454A1 (de) | 1980-08-07 |
| DE3001454C2 true DE3001454C2 (OSRAM) | 1990-05-10 |
Family
ID=20337129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19803001454 Granted DE3001454A1 (de) | 1979-01-29 | 1980-01-16 | Stabiles, prostaglandin-haltiges arzneimittel |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4352790A (OSRAM) |
| JP (1) | JPS55102512A (OSRAM) |
| BE (1) | BE881351A (OSRAM) |
| DE (1) | DE3001454A1 (OSRAM) |
| DK (2) | DK160739C (OSRAM) |
| FR (1) | FR2447191A1 (OSRAM) |
| GB (1) | GB2041220B (OSRAM) |
| NL (1) | NL190693C (OSRAM) |
| NO (1) | NO153520C (OSRAM) |
| SE (2) | SE431821B (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5079009A (en) * | 1979-03-21 | 1992-01-07 | National Research Development Corporation | Controlled release compositions including polyethylene oxide with urethane cross-linking |
| AU537741B2 (en) * | 1979-03-21 | 1984-07-12 | British Technology Group Limited | Controlled release compositions |
| IT1131833B (it) * | 1980-06-20 | 1986-06-25 | Crinos Industria Farmaco | Eccipienti per sostanze spermicide |
| ZA831186B (en) * | 1982-03-22 | 1983-11-30 | Upjohn Ltd | Gelled pge2/triacetin solutions |
| AU546872B2 (en) * | 1982-06-16 | 1985-09-26 | Unilever Plc | Skin treatment compositions containing a fatty acid or ester |
| US4675182A (en) * | 1983-02-12 | 1987-06-23 | Bayer Aktiengesellschaft | Complexes of prostaglandins |
| DE3307816A1 (de) * | 1983-03-02 | 1984-09-06 | Schering AG, 1000 Berlin und 4709 Bergkamen | Prostaglandin-haltiges pharmazeutisches praeparat und seine herstellung |
| GB8403360D0 (en) * | 1984-02-08 | 1984-03-14 | Erba Farmitalia | Pharmaceutical compositions |
| DE3428264A1 (de) * | 1984-07-27 | 1986-03-06 | Schering Ag | Gelhaltige pharmazeutische zubereitungen |
| IE59361B1 (en) | 1986-01-24 | 1994-02-09 | Akzo Nv | Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension |
| JP2590358B2 (ja) * | 1988-03-01 | 1997-03-12 | 正雄 五十嵐 | 子宮内膜症治療用の子宮内又は膣内投与製剤 |
| JPH03220201A (ja) * | 1988-11-18 | 1991-09-27 | Eisai Co Ltd | プロスタグランジン類と多糖類の結合体 |
| CH678697A5 (OSRAM) * | 1989-04-03 | 1991-10-31 | Warner Lambert Co | |
| WO1993008804A1 (fr) * | 1991-11-08 | 1993-05-13 | Kyoto Pharmaceutical Industries, Ltd. | Preparation pharmaceutique contenant un compose de prostaglandine a administrer par voie rectale ou vaginale |
| US6946442B2 (en) * | 1994-11-30 | 2005-09-20 | Asif Syed Ahmed | Method of hastening cervical ripening |
| DK0828495T3 (da) * | 1995-06-01 | 2003-02-24 | Searle & Co | Misoprostolholdige faste stabiliserede dispersioner |
| WO1999002147A1 (en) | 1997-07-09 | 1999-01-21 | Androsolutions, Inc. | Improved methods and compositions for treating male erectile dysfunction |
| US6103765A (en) | 1997-07-09 | 2000-08-15 | Androsolutions, Inc. | Methods for treating male erectile dysfunction |
| FR2766709B1 (fr) * | 1997-07-31 | 2000-04-07 | Dominique Cingotti | Procede pour la preparation d'un extrait de principes actifs sous forme de microgranules a base de fibres alimentaires entierement solubles destines a differentes formes galeniques |
| US5891915A (en) * | 1998-05-01 | 1999-04-06 | Wysor; Michael S. | Method for enhancing female sexual response and an ointment therefor |
| US6031002A (en) * | 1998-05-01 | 2000-02-29 | Michael Ebert | Method for enhancing female sexual response and a composition therefor |
| US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| US20070191320A1 (en) * | 1998-12-10 | 2007-08-16 | Nexmed Holdings, Inc. | Methods of treatment for female sexual arousal disorder |
| GR1004266B (el) * | 2001-04-30 | 2003-06-18 | Ηλιας Κ. Παπαδοπουλος | Φαρμακευτικο παρασκευασμα για την διαγνωση και θεραπεια της στυτικης δυσλειτουργιας |
| US20050181030A1 (en) * | 2003-01-03 | 2005-08-18 | Mo Y. J. | Topical stabilized prostaglandin E compound dosage forms |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3948254A (en) * | 1971-11-08 | 1976-04-06 | Alza Corporation | Novel drug delivery device |
| US3875300A (en) * | 1972-12-18 | 1975-04-01 | Ortho Pharma Corp | Composition for sustained release of a medicament and method of using same |
| US3888975A (en) * | 1972-12-27 | 1975-06-10 | Alza Corp | Erodible intrauterine device |
| US4036954A (en) * | 1973-11-02 | 1977-07-19 | Yamanouchi Pharmaceutical Co., Ltd. | Stable prostaglandin E group-containing formulation |
| AR205997A1 (es) | 1973-11-21 | 1976-06-23 | American Cyanamid Co | Resina de poliester normalmente solida biodegradable e hidrolizable |
| CH616694A5 (en) * | 1974-06-27 | 1980-04-15 | Ciba Geigy Ag | Process for the preparation of crosslinked, water-insoluble, hydrophilic copolymers |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| JPS5256148A (en) * | 1975-10-16 | 1977-05-09 | Agency Of Ind Science & Technol | Process for preparing active substances having improved |
| GB1554783A (en) | 1976-01-05 | 1979-10-31 | Population Res Inc | Pharmaceutical compositions for use in the permanent sterilization of female animals |
| US4145555A (en) * | 1976-03-12 | 1979-03-20 | Ono Pharmaceutical Company | Δ3 -Prostaglandin analogs |
| GB1551620A (en) * | 1976-12-13 | 1979-08-30 | Ici Ltd | Delivery means for biologically active agents |
-
1979
- 1979-01-29 SE SE7900737A patent/SE431821B/sv not_active IP Right Cessation
- 1979-12-17 SE SE7910354A patent/SE442167B/sv not_active IP Right Cessation
-
1980
- 1980-01-14 GB GB8001176A patent/GB2041220B/en not_active Expired
- 1980-01-16 DE DE19803001454 patent/DE3001454A1/de active Granted
- 1980-01-16 US US06/112,563 patent/US4352790A/en not_active Expired - Lifetime
- 1980-01-18 JP JP519880A patent/JPS55102512A/ja active Granted
- 1980-01-23 NL NL8000426A patent/NL190693C/xx not_active IP Right Cessation
- 1980-01-25 NO NO800186A patent/NO153520C/no unknown
- 1980-01-25 BE BE0/199113A patent/BE881351A/fr not_active IP Right Cessation
- 1980-01-28 DK DK033580A patent/DK160739C/da not_active IP Right Cessation
- 1980-01-28 FR FR8001797A patent/FR2447191A1/fr active Granted
-
1986
- 1986-07-03 DK DK316186A patent/DK160740C/da not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SE7900737L (sv) | 1980-07-30 |
| JPS55102512A (en) | 1980-08-05 |
| NO153520C (no) | 1986-04-09 |
| SE442167B (sv) | 1985-12-09 |
| FR2447191A1 (fr) | 1980-08-22 |
| SE431821B (sv) | 1984-03-05 |
| JPH0140013B2 (OSRAM) | 1989-08-24 |
| NL190693B (nl) | 1994-02-01 |
| DK160739B (da) | 1991-04-15 |
| SE7910354L (sv) | 1980-07-30 |
| NL190693C (nl) | 1994-07-01 |
| US4352790A (en) | 1982-10-05 |
| DK33580A (da) | 1980-07-30 |
| NO153520B (no) | 1985-12-30 |
| BE881351A (fr) | 1980-05-16 |
| DE3001454A1 (de) | 1980-08-07 |
| DK316186D0 (da) | 1986-07-03 |
| DK160740C (da) | 1991-09-30 |
| GB2041220A (en) | 1980-09-10 |
| DK160739C (da) | 1991-09-30 |
| GB2041220B (en) | 1983-07-27 |
| NO800186L (no) | 1980-07-30 |
| DK160740B (da) | 1991-04-15 |
| FR2447191B1 (OSRAM) | 1983-07-22 |
| DK316186A (da) | 1986-07-03 |
| NL8000426A (nl) | 1980-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3001454A1 (de) | Stabiles, prostaglandin-haltiges arzneimittel | |
| DE3486448T2 (de) | Bioadhäsive Mittel | |
| DE69323442T2 (de) | Flüssige pharmazeutische Formulierung mit verlängerter Wirkstoffabgabe | |
| KR940011241B1 (ko) | 고점성 하이드로겔 또는 현탁액 형성용 약학적 제제의 제조방법 | |
| DE69622510T2 (de) | Nifedipinzubereitung mit langanhaltender Freisetzung | |
| DE69914928T2 (de) | Polymerkomplexe von glukuronoglukanen | |
| DE69124109T2 (de) | Gelbildende flüssigträger-zusammensetzung | |
| DE69110969T2 (de) | Verwendung von Triclosan zur Behandlung von Krankheiten des Gastrointestinaltraktes. | |
| DE3750145T2 (de) | Zusammensetzung mit kontrollierter Freisetzung von Dihydrocodein. | |
| DE69600620T2 (de) | Arzneimittel mit gesteuerter wirkstofffreisetzung für basische schwerlösliche wirkstoffe | |
| DE3787829T2 (de) | System für die Periodontaltasche zur kontrollierten Drogenfreisetzung. | |
| DE69111821T2 (de) | In einem nichtwässrigen perfluorierten trägermedium suspendierte wirkstoffabgabevehikel. | |
| DE2755505C2 (de) | Mittel für die verzögerte Abgabe eines biologischen Wirkstoffs | |
| DE60103894T2 (de) | Sprühfähige Wundversorgungszusammensetzungen | |
| DE2323686A1 (de) | Arzneimittelzubereitungsform mit langzeitwirkung und verfahren zu ihrer herstellung | |
| DE3050131T1 (de) | Improvements to methods for preparing galenical preparation with delayed action and programmed release and galenical preparations for drugs obtained thereby | |
| EP0048323A1 (de) | Wundbehandlungsmittel in Pulverform und Verfahren zu seiner Herstellung | |
| CH672598A5 (OSRAM) | ||
| DE3503679C2 (OSRAM) | ||
| AT390882B (de) | Verfahren zur herstellung eines spermientoetenden, wasserfreien mittels zur lokalen empfaengnisverhuetung | |
| EP0181287B1 (de) | Trockensubstanzen und stabile Suspensionen | |
| CH639560A5 (en) | Pharmaceutical preparation having a prolonged uniform active compound release | |
| DE69105134T2 (de) | Pharmazeutische zusammensetzung. | |
| DE60030319T2 (de) | Gelzubereitung enthaltend einen gelösten oder suspendierten wirkstoff,insbesondere zur anwendung auf einer schleimhaut und herstellungsverfahren | |
| CH678697A5 (OSRAM) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8125 | Change of the main classification |
Ipc: A61K 31/557 |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |